Viewing nowCombinationTraKey Duo Tablet 2.5/500 mg
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.

MFDS item code 202201611 · Approved 2022.04.19 · Insurance code 671707350
Improves blood glucose control in patients with type 2 diabetes mellitus
This medication helps to control blood sugar levels in patients with type 2 diabetes by taking linagliptin and metformin together. It provides additional blood sugar improvement effects to patients who are also undergoing dietary control and exercise therapy. This helps in effectively managing blood sugar levels and preventing the worsening of diabetes symptoms. Therefore, this medication is very useful for the treatment of type 2 diabetes.
The dosage of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients whose blood glucose is not adequately controlled with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide a dose equivalent to linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s existing metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral blood glucose-lowering agents. Any change in the treatment regimen for type 2 diabetes may lead to changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), provided they do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustments. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).
This medication may cause serious side effects such as lactic acidosis, so it should not be used by patients with impaired kidney function or those with heart disease or liver disease. Additionally, it is safe to avoid administering this medication to women who are pregnant or breastfeeding, patients with acute alcohol intoxication, and those in a state of severe infection or trauma. This medication can cause hypoglycemia; therefore, when used in conjunction with insulin or sulfonylureas, blood sugar levels should be checked frequently, and dosages may need to be adjusted as necessary. Elderly patients with impaired kidney function or those taking other medications that may affect renal function should undergo regular kidney function tests and adjust the medication dosage as needed. Skin conditions such as acute pancreatitis or bullous pemphigoid may occur while taking this medication, so if abdominal pain or skin blisters develop, the doctor should be informed immediately. Due to the possibility of vitamin B12 deficiency, it is advisable to regularly monitor blood levels of vitamin B12 during prolonged use. If undergoing radiological tests involving iodinated contrast agents, treatment with this medication should be paused for at least 48 hours before and after the administration of the contrast agent, and kidney function should be re-evaluated. Patients scheduled for surgery should discontinue use of this medication 48 hours prior to the procedure and resume only after normal recovery of kidney function post-surgery. Women planning pregnancy or currently pregnant should avoid this medication and insulin therapy is recommended for blood sugar control. This medication is not recommended for children under 10 years of age or adolescents aged 10 to 17, as its safety and efficacy have not been established in these populations. This medication should be kept out of reach of children and stored away from moisture.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture, preferably at room temperature between 1 and 30 degrees. Proper storage will help maintain its efficacy and safety.
Light yellow, oval-shaped, biconvex film-coated tablet
60 tablets/Alu-Alu[60 tablets (10 tablets/Alu-Alu x 6)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.